Bardet-Biedl Syndrome

Overview

Bardet-Biedl syndrome (BBS) is a rare inherited disorder in which changes in genes needed for the function of primary cilia—tiny cell structures that help cells sense and communicate—affect many organs. Common features include progressive retinal degeneration and vision loss, early-onset obesity with intense hunger, extra fingers or toes, kidney abnormalities, differences in sexual development, and variable learning or developmental difficulties. BBS consensus recommendations Prognosis varies substantially, but progressive retinal disease and chronic kidney disease are major long-term concerns. BBS consensus recommendations

There is no approved cure that corrects BBS throughout the body. Current care is multidisciplinary and includes genetic diagnosis; regular eye, kidney, metabolic, developmental, and endocrine monitoring; low-vision rehabilitation; and treatment of individual complications. BBS consensus recommendations For obesity associated with BBS, the MC4R-pathway drug setmelanotide is approved in the United States for patients aged 2 years and older, but it does not repair the disease-causing gene changes or reverse retinal degeneration. Current U.S. setmelanotide label

Scope of Recent Research (2020–present)

Research activity has accelerated from symptom control toward precision treatments for the most disabling manifestations, especially inherited retinal degeneration. The dominant questions are whether supplying a healthy copy of an individual BBS gene can preserve living photoreceptors, how early treatment must occur, and whether therapies can eventually address non-eye manifestations such as obesity and kidney disease. BBS10 retinal gene-therapy study The field has reached first-in-human and compassionate-use retinal gene therapy, but a whole-body curative therapy remains distant because BBS involves many genes, tissues, and developmental effects. AXIS BBS1 trial record

Major Breakthroughs and Emerging Therapies

The clearest preclinical breakthrough has been retinal gene augmentation: delivering a working gene copy rather than changing the patient’s own DNA sequence. In a BBS10 knockout mouse model, a subretinal injection of an adeno-associated virus (AAV) vector carrying Bbs10 slowed photoreceptor death, preserved retinal electrical responses and structure, restored detectable cone-cell function, and delayed functional vision loss. BBS10 retinal gene-therapy study This is preservation and partial functional rescue in mice—not proof of restored normal eyesight or a human cure. BBS10 retinal gene-therapy study

Timing has emerged as a decisive issue. A 2025 study in mice treated at a more advanced stage found better preservation of rod-driven retinal responses and retinal thickness, but no significant cone-response benefit; the investigators concluded that earlier treatment is likely needed to preserve high-acuity, cone-mediated vision. Later-stage BBS10 gene therapy in mice This supports early molecular diagnosis and retinal monitoring so that treatment can occur while viable photoreceptors remain. BBS consensus recommendations

For BBS1-related retinal degeneration, Axovia Therapeutics has developed AXV-101, an AAV9 vector designed to deliver a codon-optimized human BBS1 gene. AXV-101 preclinical presentation The corresponding AXIS study is a first-in-human, open-label dose-escalation study designed principally to establish safety, tolerability, dose, drug distribution, and preliminary retinal changes after one treated eye; it therefore should not be interpreted as evidence of clinical efficacy yet. AXIS BBS1 trial record

BBS10 gene replacement has also crossed an important translational threshold. MeiraGTx has manufactured an AAV8 vector carrying human BBS10 for treatment under the United Kingdom’s MHRA “Specials” pathway, a tightly controlled compassionate-use route rather than a conventional clinical trial. MeiraGTx annual report By July 2026, two young people had received this subretinal therapy at St Helier Hospital, including the first procedure in August 2025; public reports did not provide formal, peer-reviewed efficacy outcomes. St Helier BBS10 treatment report

Small-molecule treatment has made real progress for the metabolic component of BBS, although it is not curative. Setmelanotide activates melanocortin-4 receptor signaling downstream of the cilia-related defect that contributes to hyperphagia; in the pivotal phase 3 study, 32.3% of BBS participants aged 12 years or older achieved at least 10% weight loss after 52 weeks. Phase 3 setmelanotide trial A 2026 prospective observational study of 26 patients also associated six months of treatment with lower hyperphagia scores, lower BMI z scores, and improvements in liver-fat measures and estimated kidney filtration, findings that require confirmation in longer controlled studies. Setmelanotide metabolic and kidney study

Clinical Trials and Experimental Approaches

The principal registered disease-modifying trial is AXIS (NCT07269665), sponsored by Axovia Therapeutics. It is an early phase 1, single-dose, open-label dose-escalation study of AXV-101 for children with biallelic BBS1 variants and retinal degeneration, with estimated enrollment of 12 participants and comparison of treated and untreated eyes through structural and functional eye assessments. AXIS BBS1 trial record The latest ClinicalTrials.gov record posted on March 31, 2026 listed the study as not yet recruiting and projected primary completion in February 2027; no results have been posted. AXIS BBS1 trial record

The completed phase 3 setmelanotide trial (NCT03746522), sponsored by Rhythm Pharmaceuticals, was a 14-week randomized, placebo-controlled study followed by 52 weeks of open-label treatment. Phase 3 setmelanotide trial It established a treatment for BBS-related obesity and hunger, but not for visual loss, kidney disease, developmental features, or the underlying genetic disorder. Current U.S. setmelanotide label The BBS10 Specials cases are clinically meaningful pioneering treatments, but they are not a registered efficacy trial and should not be used to infer benefit until systematic outcomes are reported. MeiraGTx annual report

Methodologies and Scientific Approaches

Researchers combine genotype-specific animal models with detailed retinal measurements. In BBS10 mice, studies have used optical coherence tomography (OCT) to measure retinal layers, electroretinography (ERG) to assess retinal electrical responses, retinal histology, and visually guided swim tasks to determine whether cell-level rescue translates into usable vision. BBS10 retinal gene-therapy study Larger-animal work is also important: a naturally occurring BBS7 rhesus macaque model has retinal, kidney, and other features relevant to BBS and offers a bridge between mouse findings and human eye anatomy. Retinal degeneration models in BBS

The main delivery platform is localized subretinal AAV injection, which can place a gene therapy near surviving photoreceptors while limiting whole-body exposure. St Helier BBS10 treatment report Investigators are also studying approaches that may work across more than one BBS gene: in a BBS mouse model, restoring the cilia-regulating enzyme INPP5E corrected abnormal olfactory cilia and improved odor detection, identifying a possible downstream, gene-agnostic target. INPP5E and olfactory rescue in ciliopathies

Leading Institutions and Funding

The University of Iowa’s ophthalmology and genetics teams, including the Drack, Sheffield, and Seo research groups, produced the foundational BBS10 mouse gene-augmentation work. BBS10 retinal gene-therapy study Axovia Therapeutics is sponsoring the BBS1 AXIS trial, with Moorfields Eye Hospital identified as a trial site, while MeiraGTx developed and manufactured the BBS10 vector used through the UK Specials program. AXIS BBS1 trial record St Helier BBS10 treatment report

Patient organizations remain unusually important in this ultra-rare disease. The Bardet-Biedl Syndrome Foundation received an $800,000, five-year Chan Zuckerberg Initiative Rare As One Network grant at the end of 2024 to build patient-centered research infrastructure and collaboration. BBS Foundation history and CZI grant NIH support also funds foundational BBS biology; for example, a University of Washington project on BBS protein biology reported $127,157 in total funding for fiscal year 2021. NIH RePORTER BBS project

Strengths, Limitations, and Challenges

A major strength is that the eye is accessible for imaging and local treatment, allowing researchers to measure structural and functional changes in a treated eye against an untreated eye. AXIS BBS1 trial record The BBS10 mouse data show that gene replacement can preserve photoreceptors and meaningful vision-related behavior, and the transition to BBS1 phase 1 testing and BBS10 compassionate use demonstrates that the field has moved beyond theory. BBS10 retinal gene-therapy study St Helier BBS10 treatment report

The limits are equally important. Retinal AAV treatments are gene-specific and treat only the eye, whereas BBS can result from many genes and affects the brain, kidney, metabolism, reproductive system, and development. BBS consensus recommendations They are expected to preserve remaining retinal cells rather than regenerate cells already lost, and later treatment in mice appears less able to rescue cones. Later-stage BBS10 gene therapy in mice Safety, dose, immune responses, surgical risks, durability, equitable access, and the scarcity of patients for adequately powered studies are unresolved challenges. AXIS BBS1 trial record

Outlook and Future Directions

As of September 10, 2026, BBS research is closest to a gene-specific treatment that preserves vision in selected children before extensive retinal degeneration, rather than a cure for the entire syndrome. The milestones to watch are safety and retinal-function results from AXIS, systematically reported outcomes from the BBS10 UK Specials program, expansion to additional BBS genes, and evidence that earlier genetic diagnosis can identify patients while enough photoreceptors remain to benefit. AXIS BBS1 trial record MeiraGTx annual report

References

• BBS consensus recommendations — Dollfus et al., 2024.
• Current U.S. setmelanotide label — U.S. Food and Drug Administration, 2026.
• BBS10 retinal gene-therapy study — Hsu et al., 2023.
• Later-stage BBS10 gene therapy in mice — Journal of AAPOS, 2025.
• AXV-101 preclinical presentation — Axovia Therapeutics, 2025.
• AXIS BBS1 trial record — ClinicalTrials.gov, 2026.
• MeiraGTx annual report — MeiraGTx Holdings plc, 2026.
• St Helier BBS10 treatment report — Epsom and St Helier University Hospitals NHS Trust, 2026.
• Phase 3 setmelanotide trial — Haqq et al., 2022.
• Setmelanotide metabolic and kidney study — Hühne et al., 2026.
• Retinal degeneration models in BBS — Wheway et al., 2022.
• INPP5E and olfactory rescue in ciliopathies — Xie et al., 2022.
• BBS Foundation history and CZI grant — Bardet-Biedl Syndrome Foundation, 2025.
• NIH RePORTER BBS project — National Institutes of Health, 2021.